

# SCDD COVID-19 Vaccine Community Input Sessions

December 18, 2020

---

**Aaron Carruthers**

State Council on Developmental Disabilities  
CA Community Vaccine Advisory Committee Member



# Welcome and Meeting Etiquette

- ▶ Keep microphones muted unless called on to speak
  - ▶ Captioning, Spanish and ASL interpretation is available for those needing it. Please check the chat box for instructions
  - ▶ Participant Introductions will be done via the chat box
  - ▶ Questions and Feedback
- 

# Hope

“There is a light at the end of the tunnel. We are talking about how do we get there from here”

– CA Surgeon General Nadine Burke Harris

# Purpose

- ▶ Community Vaccine Advisory Committee
  - ▶ Direct connection for you to get information, to give information
  - ▶ Share what we know, what we don't know
  - ▶ Advocacy success
  - ▶ Hear from you
- 

# Community Vaccine Advisory Committee (CVAC)

- ▶ CA Dept of Public Health
  - Scientific Safety Review Workgroup
  - Drafting Guidelines Workgroup
  - Community Vaccine Advisory Committee
- ▶ Focused on safety, transparency, and equity of vaccine and distribution
- ▶ 70 members
  - 5 representing disability and aging advocates

# Community Vaccine Advisory Committee (CVAC)

- ▶ My focus so far
  - Vaccine priority for people with intellectual, developmental, and other disabilities
  - Vaccine priority for caregivers, whether paid or not, whether family or not
  - Vaccine safety for people with complex medical conditions, and interaction with other drugs
  - Informed consent

# Vaccine(s) Approval

- ▶ Friday December 11, 2020: FDA approved Pfizer vaccine
- ▶ Thursday December 17-20: FDA reviews Moderna vaccine
- ▶ US may have 2 approved vaccines by Monday Dec 21, 2020

# CA Vaccine Dosages

- ▶ This week: CA received 327k doses
  - ▶ End of December 2020: 2 million doses
  - ▶ End of January 2021: 4 million doses
  - ▶ End of April 2021: 20 million doses
- 

# How the Vaccines Work

- ▶ Pfizer and Moderna vaccines use a genetic code to stimulate the immune response against COVID-19
- ▶ Sequence designed on a computer
  - No cells used in creation
- ▶ No live, attenuated, or inactive virus
- ▶ Not protein based
- ▶ Not a DNA vaccine

# Vaccine Ingredients

## ▶ Pfizer

- mRNA, lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3-phosphocholine, and cholesterol), potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.

# Vaccine Ingredients

## ▶ Moderna

- mRNA: the proprietary ionizable lipid SM-102; cholesterol; 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); and 1-monomethoxypolyethyleneglycol-2,3-dimyristylglycerol with polyethylene glycol of average molecular weight 2000 (PEG2000-DMG); tris buffer containing sucrose and sodium

# Vaccine Ingredients

- ▶ Mainly fats and sugars

# More About the Vaccine

- ▶ Need to be shipped and stored cold
  - Pfizer -70 degrees Celsius
  - Moderna -20 degrees Celsius
  
- ▶ Both need 2 doses for full immunity
  - 1st = 50% immunity
  - 2<sup>nd</sup> = 95% immunity
  - 21-28 days apart

# More About the Vaccine

- ▶ Not known if it prevents transmission
  - We do not yet know whether vaccinated people can spread the virus
  
- ▶ So keep your good practices
  - Face masks
  - Wash hands
  - 6' apart

# More About the Vaccine

- ▶ Pfizer clinical trials:
  - 40,000 trial participants
    - 10,000 Latinx/Hispanic
    - 3,500 African- American
    - 1,600 Asian
- Comorbidities
  - Obesity
  - Diabetes
  - Respiratory
  - Cardiac

# More About the Vaccine

- ▶ Children not included in clinical trials
- ▶ FDA approved Pfizer vaccine for people 16 years or older
- ▶ Pfizer and Moderna to start clinical trials on younger people
  - 14-15
  - 12-13

# More About the Vaccine

- ▶ Pfizer side effects
  - 91.6% injection site pain
  - 68.5% fatigue
  - 63.0% headache
  - 59.6% muscle pain
- No anaphylactic or severe hypersensitivity reactions

# Scarcity: Setting Priorities

- ▶ Currently there is not enough supply to immunize all persons who are willing to accept the vaccine
- ▶ Therefore, California is crafting a fair, equitable, evidence-based, and transparent policy to prioritize those who should be offered the vaccine initially until the capacity to manufacture and administer the vaccine increases

# First Priority: Health Care Workers

- ▶ Health care workers are priority 1A because its members play critical roles in maintaining capacity of California's health system and sustaining health services during the COVID-19 pandemic, both for those with COVID-19 and for those who need care due to other causes.

# First Priority: Health Care Workers

- ▶ Broad definition of health care workers
- ▶ Tier 1A includes:
  - **“Workers who provide support to vulnerable populations to ensure their health and well-being including family care providers.”**
  - **"Home health care and in-home supportive services"**

# First Priority: People with IDD & other disabilities

- ▶ Advocating that people with IDD, other disabilities and older Californians be included in Tier 1B
- ▶ Can be done by stating “any person receiving HCBS services are eligible”
- ▶ This recommendation being considered

# Distribution

- ▶ Local County Public Health Departments will administer for each county

# Questions and Concerns

- ▶ How will public health recognize health care providers who work in homes rather than hospitals?
  - ▶ How can vaccines be done in-home?
  - ▶ How safe is the vaccine?
  - ▶ What are interactions with other medications?
- 

# Time to hear from you

- ▶ SCDD is gathering DD community's thoughts and feelings about the COVID-19 vaccine
- ▶ Doing this through a survey and these community conversations
- ▶ While your individual information will not be shared with anyone, SCDD may share the results with the public agencies such as the California Vaccine Community Advisory Committee.

# Question 1

- ▶ When the COVID-19 vaccine becomes available, will you get it?

# Question 2

What is your biggest concern about the COVID-19 vaccine?

- Side effects?
- Cost?
- How well the vaccine works?
- Something else?

# Question 3

- ▶ What do you most want to know to decide if the vaccine is right for you, your family, or those you care for?

# Question 4

- ▶ Any other questions you have?

# Next Steps

- ▶ Your feedback informs SCDD's comments to CVAC
- ▶ FAQ
- ▶ You can communicate with CVAC
  - [COVID19VaccineOutreach@cdph.ca.gov](mailto:COVID19VaccineOutreach@cdph.ca.gov)
- ▶ Conversations in 2021

# State Council Contact Information

- ▶ Email: [scdd@scdd.ca.gov](mailto:scdd@scdd.ca.gov)